Erdogan, Ayse2026-01-242026-01-2420250091-150X1573-9031https://doi.org/10.1007/s11094-025-03462-5https://hdl.handle.net/20.500.12868/5554Green tea catechins, especially epigallocatechin-3-gallate (EGCG), have been associated with cancer prevention and treatment. Cetuximab is a chimeric monoclonal antibody that is directed toward the epidermal growth factor receptor (EGFR). The use of EGCG could enhance the effect of cetuximab through additive or synergistic effects as well as through amelioration of deleterious side effects. Cytotoxic, antiproliferative, cell-cycle-inhibitory, oxidative, and apoptotic effects of cetuximab alone and together with EGCG on A-549 and H1299 cells were investigated. EGCG enhanced cytotoxic effect of cetuximab on all cells. Lactate dehydrogenase activity, as a result of cell death, was found to be at the highest level at treatment of cetuximab with EGCG in all cells. Treatment of cetuximab with EGCG was found to be more effective at increasing glutathione peroxidase activity than cetuximab alone. Proliferating Cell Nuclear Antigen (PCNA), topoisomerase II-alpha, cyclin D1, cyclin D2, cyclin E, cyclin A, and cyclin B gene expression was decreased in all cells, which explains the cell-cycle-inhibitory effect. Both cetuximab alone and in combination treatments caused an increase in the Bax/Bcl-2 ratio in both type of cell. These findings suggest that treatment of cetuximab combined with EGCG might exhibit more carcinogenesis-reducing potential than cetuximab alone.eninfo:eu-repo/semantics/closedAccessepigallocatechin-3-gallatecetuximabapoptosislung cancercombined treatmentArticle10.1007/s11094-025-03462-55988378482-s2.0-105024922815Q4WOS:001637685600001Q4